Introduction
============

The burnout syndrome poses an increasing challenge to socioeconomics in the Western world.[@b1-ndt-13-889] This study reports an exploratory clinical trial investigating clinical outcomes of *Rhodiola rosea* treatment in patients suffering from burnout symptoms.

The core indicators of the syndrome are subjective perceptions of chronic demand-related stress with subsequent emotional exhaustion and decreased performance in work-related or self-set tasks.[@b1-ndt-13-889]--[@b9-ndt-13-889] Reported symptoms of burnout are manifold, comprising not only psychiatric or mood disorders such as fatigue, cynicism, impaired sexual life, lack of concentration, or a generally negative attitude toward work, but also somatic symptoms such as headaches, hypertonia, or irritable stomach.[@b6-ndt-13-889],[@b9-ndt-13-889] It is also agreed that the development of the syndrome bears a considerable risk of subsequent serious mental or somatic disorders, among which depression, anxiety, and cardiovascular conditions are the most prevalent indications associated with a history of burnout.[@b3-ndt-13-889],[@b10-ndt-13-889]--[@b13-ndt-13-889]

Support in preventing and alleviating stress reactions is offered by adaptogenic substances which are reported to potentially enhance individual stress tolerance.[@b14-ndt-13-889]--[@b18-ndt-13-889] *R. rosea* is one of the most popular herbal medicinal plants with adaptogenic properties.[@b19-ndt-13-889] As in all adaptogens, the pharmacodynamic characteristics of *R. rosea* include near-non-toxicity and a nonspecific effect that increases the resistance of the organism to adverse biochemical and physical factors.[@b14-ndt-13-889] Unlike proper central nervous system stimulants, *R. rosea* is reported to enhance the performance without causing a subsequent substantial decrease in work capacity and to provide mental stimulation combined with emotional stabilization.[@b12-ndt-13-889],[@b18-ndt-13-889],[@b20-ndt-13-889]--[@b22-ndt-13-889]

The roots and rhizomes of *R. rosea* contain several medically active compounds, that is, phenolic acids, triterpenes, monoterpenes, flavonoids, phenylethanol derivatives, and the phenylpropanoids such as rosavin, rosin, and rosarin. The latter have as yet only been found in *R. rosea*.[@b23-ndt-13-889] *R. rosea*'s dry extract has a long tradition as a herbal medicinal product administered for alleviating stress-related symptoms such as fatigue or sensation of weakness.[@b14-ndt-13-889]

Based on this knowledge, various clinical trials have recently assessed *R. rosea* in subjects with stress-related conditions. Edwards et al demonstrated not only a clinically relevant improvement in subjects suffering from life-stress symptoms after administration of *R. rosea* extract but also the safety of the drug.[@b24-ndt-13-889] Other trials evaluating the effects of *R. rosea* extract in improving the physical and mental performance under stressful conditions confirm and support these findings.[@b25-ndt-13-889],[@b26-ndt-13-889]

Investigating the effects of *R. rosea* on burnout-related symptoms, Olsson et al demonstrated the superiority of *R. rosea* extract over placebo in alleviating mental fatigue as measured by the Pines burnout scale.[@b27-ndt-13-889] A German noninterventional study conducted in 128 general practitioner (GP) practices including 330 patients with two or more burnout indicator symptoms, as assessed on a basic, self-rating questionnaire, also reported a considerable alleviation of these symptoms after the administration of *R. rosea* extract for 8 weeks.[@b28-ndt-13-889] Beneficial effects of *R. rosea* extract on emotional instability and somatization as symptoms of mild to moderate depression were demonstrated by Darbynian et al.[@b29-ndt-13-889] This is of particular interest as these symptoms -- when associated with stress -- are also regarded as indicators of burnout.[@b6-ndt-13-889],[@b9-ndt-13-889]

Both traditional knowledge and the results of these recent studies support the use of *R. rosea* for stress-related symptoms such as fatigue or lack of performance. These findings suggest that *R. rosea* might also be beneficial in burnout and that further testing of the drug in patients suffering from this stress-related syndrome is warranted.

The trial reported here not only investigated individual aspects of stress-related conditions and indicators of burnout but aimed to cover as many aspects as possible, including individual perceptions of stress and exhaustion, and to compare these with objective assessments. Thus, a rounded set of criteria for the evaluation of the clinical course in burnout was provided. This trial is therefore the first to investigate the clinical outcomes of *R. rosea* treatment in patients with predefined burnout symptoms based on numerous specific criteria and measurements.

Objective
=========

The trial presented in this study is the first to investigate the clinical outcomes of the drug treatment in patients suffering from burnout syndrome. The principal objective of the trial was therefore to describe the therapeutic impacts as well as the safety and tolerability of *R. rosea* extract applied in this target group, thus providing exploratory data as a basis for future randomized trials.

Methods
=======

According to its exploratory design, which aimed to evaluate the study data on a descriptive level, the trial was set up as an open-label, single-arm, multicenter study. Control groups and randomization were therefore unnecessary. The trial was conducted at four centers in Vienna (Austria): Vienna University Hospital and three GP practices. Signed informed consent was obtained from the participants before any trial-related action was performed. The clinical trial number for this study is ISRCTN31235821. The clinical trial was approved by the Ethikkommission der Medizinischen Universität Wien und des AKH, Borschkegasse 8b/E06, A-1090 Wien, Vienna, Austria, which officiated as the responsible ethics committee. Planning, execution, and analysis of the trial were carried out in accordance with national regulations in Austria and the ICH Guidelines for Good Clinical Practice (GCP).

Participants
------------

The trial aimed to recruit 120 male and female employees or subjects with comparable stress burdens (eg, home caring of handicapped or demented family members) aged 30--60 years suffering from burnout symptoms.

Outcome measures
----------------

Since no data are available in this study-specific target population, the following broad spectrum of outcome measures was employed to evaluate the clinical courses in patients suffering from burnout symptoms.

The Maslach Burnout Inventory (MBI-D),[@b1-ndt-13-889] seven Numerical Analogue Scales (NASs) of subjective stress symptoms, one *NAS* to assess the "overall satisfaction with sexual life," the Burnout Screening Scales (BOSS I and BOSS II),[@b30-ndt-13-889] the Patient Sexual Function Questionnaire (PSFQ),[@b31-ndt-13-889],[@b32-ndt-13-889] and the Perceived Stress Questionnaire (PSQ).[@b33-ndt-13-889] The Clinical Global Impressions Scale (CGI)[@b34-ndt-13-889] were used to assess the severity of the disorder and its change from baseline, clinical outcomes, and the tolerability of the study medication. Mood and well-being were measured by means of the Multidimensional Mood State Questionnaire (MDMQ).[@b35-ndt-13-889] These tools were all self-rating instruments. In addition, the following objective scales were employed: the Sheehan Disability Scale (SDS)[@b36-ndt-13-889] to assess the negative impact of the burnout symptoms on the patient's work, social life, and family, and the Number Connection Test (NCT)[@b37-ndt-13-889] to assess speed of executive function.

Eligibility
-----------

The inclusion criteria were as follows: moderate degree of burnout with an emotional exhaustion level of 1.81--2.80 and a reduced personal performance level of 3.90--4.79 according to the MBI-D, at least three perceived life stress symptoms with a severity between 5 and 8 points as assessed on NASs of subjective stress symptoms, a CGI item 1 score \<4, and \>5 points on the NAS for impairment of sexual life.

Patients with any of the following characteristics were excluded: Participation in other experimental drug trials within 12 weeks before enrollment, current hospitalization, risk of suicide or item 3 of the Hamilton Rating Scale for Depression (HAM-D)[@b38-ndt-13-889] \>2, history or evidence of substance abuse or dependence, history of Axis I disorders according to DSM-IV, nonmedical psychiatric treatment at least 4 weeks before the study, intake of any prescribed psychotropic medication within 1 year before enrollment, and known hypersensitivity to *R. rosea* extract or any ingredient of the drug under study.

Concomitant treatment prohibited for study participants also included treatment for neurodegenerative diseases, centrally acting antihypertensive medication (exception: beta-blockers on dosage stable for at least 4 weeks), and muscle relaxants.

Laboratory tests and electrocardiogram (ECG) were assessed for abnormalities. Existing cardiovascular, respiratory, cerebrovascular, or metabolic disorders as well as infections, epilepsy, Parkinson's disease, and progressive diseases such as cancer precluded inclusion. Subjects with generalized anxiety disorder according to module O of the Mini International Neuropsychiatric Interview (MINI)[@b39-ndt-13-889] or major depression according to module A of the MINI and having a total score ≥16 on the HAM-D (17-item version) at screening were also excluded from the trial.

Intervention
------------

The active ingredient of the preparation is a proprietary dry ethanolic (60% w/w) extract from *R. rosea* roots (1.5--5:1) (WS^®^ 1375, Rosalin; which is the active substance of Vitango^®^, manufactured by Dr Willmar Schwabe GmbH & Co, KG, Germany). Evidence from previously conducted clinical trials[@b24-ndt-13-889],[@b26-ndt-13-889],[@b29-ndt-13-889] indicates the 400 mg/day dosage of study medication chosen for this study to be in an effective and a safe administration range.

After the determination of trial eligibility, the patients were screened for inclusion and exclusion criteria on day-2. Patients were enrolled upon meeting all the criteria, and written informed consent was obtained from all the patients. After the baseline visit (day 0), patients underwent a treatment with 200 mg of *R. rosea* extract administered twice daily over a treatment duration of 12 weeks. Patients were asked to take one 200 mg tablet before breakfast and one before lunch with a glass of water.

Regular visits were scheduled for days 0 and 7 as well as for weeks 4 (telephone interview), 8, and 12 (termination visit). Given the comparatively long treatment duration chosen for the trial, this schedule of visits was set in order to allow the investigators to capture data regarding both short-term and delayed impacts of the study medication.

All the outcome variables were measured at screening and at week 12. BOSS I was additionally assessed at week 8, whereas BOSS II, NASs for subjective stress symptoms, NCT, MDMQ, and CGI were additionally assessed at day 7 and week 8.

Safety and tolerability were assessed by physical examination, vital sign measurements, 12-lead ECG, and laboratory tests at screening and end of treatment. The patients were asked about adverse events (AEs) and concomitant medication at every visit. The severity and causal relationships of AEs with the test drug were classified by the respective investigator according to standards set by ICH-GCP.

Statistical methods
-------------------

The rating scales were assessed and evaluated in an exploratory data analysis in order to support the results of earlier trials regarding the treatment of mental and physical symptoms of stress and overwork such as fatigue and exhaustion. Therefore, no hypotheses were formulated and no formal estimation of sample size accounting for type I error rate, power, standard deviation, and effect size was done. Because of the exploratory characteristics of the trial, no adjustments for multiplicity were applied.

The sample size of 120 participants was regarded as sufficient in order to obtain primary information about the clinical outcomes in the target group and to derive estimates regarding variability. Calculations were based on a one-group multivariate repeated measures design for a two-sided test, five time points, and a descriptive significance level α=0.5. This results in a power of 80% to detect a minimum standardized difference of 0.5 when recruiting 120 participants -- including a 10% dropout rate.[@b40-ndt-13-889]

The absolute and relative intra-individual changes during the time courses of the outcome parameters were evaluated. Descriptive statistics were computed to describe the empirical distributions, 95% confidence intervals for the expected values and medians were calculated, and descriptive *P*-values associated with appropriate statistical tests were presented. In order to analyze not only the main effects but also the interaction effects on various outcome variables, for example, between time and gender, repeated measurement analysis of variance was applied. Statistical analysis was performed by a CRO using the SAS^®^ statistical software package (Statistical Analysis System; SAS Institute, Cary, NC, USA, Version 9.1.3).

The analysis was primarily based on the full analysis set (FAS) including all participants who had received at least one dose of *R. rosea* and who had had at least one post-screening measurement on one of the rating scales (MBI-D, BOSS I+II, NAS, PSQ, NCT, SDS, MDMQ, PSFQ, and CGI). In addition, a per-protocol (PP) analysis was performed including those patients of the FAS without major protocol violations. Safety variables were assessed for the safety population which included all patients who were given study medication at least once.

Results
=======

Participant flow
----------------

In total, 131 patients were screened and 118 patients were finally included in the study and received the investigational treatment at least once. The first patient was included on July 21, 2011, and the last visit of the last patient was conducted on October 24, 2012. One patient was lost to follow-up without any post-baseline measurement. Thus, 117 patients could be included in the FAS. During the treatment phase, 18 patients (15.3%) terminated the study prematurely. Major protocol violations were observed in 49 patients; therefore, a total of 68 patients were included in the per-protocol set (PPS). Most of the major protocol violations were due to reduced visit schedule compliance (n=30).

In the following, only the outcome data of the FAS are shown since the analysis of the FAS and the PPS revealed similar results. The disposition of patients and analysis data sets are illustrated in [Figure 1](#f1-ndt-13-889){ref-type="fig"}.

Demographic characteristics
---------------------------

The analysis of the MINI assessments showed that 4/117 patients (3.4%) reported a former episode of major depression, 8/117 (7%) had a low suicidal risk, whereas a current panic attack, a current agoraphobia, and a current bulimia nervosa were reported by one patient each. No further neuropsychiatric disorders were detectable among the FAS members. The analysis of the HAM-D showed an average total score (± standard deviation) of 10.2±2.5 points at screening, which indicates only mild depressive symptoms in the FAS cohort. 40/117 patients (34.2%) had already been treated for stress-related complaints in the past. The average duration of stress was 2.7±3.0 years. Demographic data are summarized in [Table 1](#t1-ndt-13-889){ref-type="table"}.

The overall treatment compliance evaluated according to the number of tablets dispensed and returned in relation to the respective number of treatment days, was high. In the FAS, the average compliance was 98.6%±6.1% with a median of 99.4%.

Clinical outcomes
-----------------

A decrease by 0.4±1.2 and 0.3±1.0 points, respectively, was observed in the MBI-D subscales "depersonalization" and "emotional exhaustion" between screening and week 12. No change could be detected in the subscales "involvement" and "personal accomplishment" ([Table 2](#t2-ndt-13-889){ref-type="table"}).

[Figure 2](#f2-ndt-13-889){ref-type="fig"} illustrates the time courses of the NASs for subjective stress symptoms. All the seven items showed significant improvement between screening and week 12, with the greatest change occurring during the first week of treatment (*P*\<0.001, two-sided Wilcoxon signed-rank test, FAS, and last observation carried forward \[LOCF\]). Subscores with the most obvious change were "exhaustion," "impaired concentration," and "somatic symptoms," with a decrease by 3.1±2.8, 2.5±2.6, and 2.4±2.5 points, respectively, at week 12.

All subscores of the PSQ as well as the total PSQ global score distinctly decreased between screening and end of the intervention period. The PSQ subscores with the greatest change after 12 weeks of administration of *R. rosea* were "lack of joy," "tension," and "fatigue," which improved by 2.8±4.1, 2.4±2.6, and 2.4±3.0, respectively ([Table 3](#t3-ndt-13-889){ref-type="table"}).

[Table 4](#t4-ndt-13-889){ref-type="table"} summarizes the total average values for the BOSS I and II assessments before and after the intervention period. The global scores as well as all subscales had improved at week 8 and also until week 12. The BOSS II interim measurement at day 7 showed an alleviation of symptoms ([Table 4](#t4-ndt-13-889){ref-type="table"} and [Figure 3](#f3-ndt-13-889){ref-type="fig"}).

The NAS score for Impairment of Sexual Life improved considerably, as well as most of the items of the PSFQ. The improvement of the "ability to have and/or maintain an erection" was marked though not statistically significant, while the "ability to ejaculate" and "relevance of sexual functioning for current wellbeing" remained mainly unchanged. For both the items, mild impairment had been reported at screening ([Table 5](#t5-ndt-13-889){ref-type="table"}).

NCT values increased distinctly between screening and week 12. All the three subscales of the MDMQ also showed marked improvement from screening to week 12 ([Table 6](#t6-ndt-13-889){ref-type="table"}).

The global impairment score measured by the *SDS* decreased from 17.8±5.8 at screening to 12.4±7.7 at week 12 (*P*\<0.001). There was also a trend toward the reduction in the subscore "work days lost" (1.0±2.3 vs 0.6±1.3, *P*=0.063) and a significant reduction in the second subscore "days being underproductive" (2.5±2.4 vs 1.5±1.8, *P*\<0.001 for the two-sided Wilcoxon signed-rank test, FAS, LOCF).

The *CGI* scores for therapeutic effects showed a "marked" improvement in 49/117 (41.9%) patients after 12 weeks of treatment, whereas the improvement of symptoms was reported to be "moderate" in 26/117 (22.2%), and "minimal" in 30/117 (25.6%) of the patients. In 8/117 patients (6.8%), symptoms were rated as unchanged or worse. Comparable results were obtained for the rating of global improvement after the treatment period, which was reported to be "very much," "much," or "minimally" the case in 41/117 (35.0%), 26/117 (22.2%), and 34/117 (29.1%) patients, respectively. The mean "severity" score had significantly dropped from 3.4±0.7 at screening to 2.4±1.1 at week 12 (*P*\<0.001).

In addition to the overall analysis, all rating scales were analyzed with regard to gender and age subgroups (separated by the median) for both the FAS and PPS. In summary, all relevant changes in outcome variables for the whole study population could also be confirmed within each subgroup.

Safety
------

The participants representing the safety population were given the investigational product between 3 and 98 days with a mean treatment duration of 81.3±18.0 days. A total of 145 AEs, which were either reported by the trial participants or revealed by the investigator at scheduled visits, were observed in 70/118 (59.3%) patients during the active treatment phase and a subsequent 7 days risk phase. AE intensity was predominantly rated as mild (59/145 \[40.7%\]) or moderate (68/145 \[46.9%\]), and severe (18/145 \[12.4%\]). For 46/145 AEs (31.7%), a causal relationship with the investigational product could not be excluded but was assessed as "unlikely" in 41/46 (89.1%) cases. A causal relationship with the study drug was rated "possible" in 5/46 (10.9%) subjects who reported head pressure, light-headedness, nausea, feeling irritated, and eye swelling. One serious adverse event (SAE) occurred in a male subject who had to be hospitalized for 3 days due to urinary tract infection after cystoscopy. The SAE was assessed as "not related" to the investigational product and had resolved at the end of the study. Except for this case of hospitalization, no other SAE was reported. The calculated overall incidence of AEs per observation day was 0.015 and was found to be low during the whole study period. None of the safety laboratory parameters presented a significant mean change during the course of the study. The AEs are summarized in [Table 7](#t7-ndt-13-889){ref-type="table"}.

Discussion
==========

Most of the outcome variables assessed in this trial demonstrated relevant improvement over time with considerable changes already being detectable after the first week of *R. rosea* administration.

As stress-induced exhaustion is regarded as an essential precondition to burnout development, this outcome was of central interest in the evaluation of study assessments. The level of "emotional exhaustion" as assessed by the MBI-D at screening was moderate and improved clearly over the time of the intervention. Likewise, the PSQ-assessed "fatigue" value and the subscore "exhaustion," as assessed by the respective NASs, had already clearly improved by day 7 and further decreased until the end of the intervention. Furthermore, the other subscales assessed by the NASs for subjective stress symptoms underwent significant improvement, which suggests an increase in coping ability and a decrease in subjectively perceived demand after the intervention.

Mood-related results improved in a similar way with "lack of joy" undergoing the greatest improvement among the values assessed by PSQ. Accordingly, there was a clear improvement of the value "loss of zest for life" as assessed by NAS, suggesting a diminished tendency toward stress-related depressive mood.

Overall, the data obtained by PSQ and the NASs for subjective stress symptoms demonstrate improvement in all the assessed values, which was most pronounced within the first week of treatment and continued slowly afterwards. The values most closely associated with burnout were among those with greatest improvement. The results suggest a development toward re-establishment of a demand--resource balance, thus supporting the findings from earlier placebo-controlled trials that investigated the clinical outcomes of *R. rosea* treatment for stress-related symptoms[@b25-ndt-13-889]--[@b27-ndt-13-889] and for the symptoms of depression.[@b29-ndt-13-889]

Although the MBI-D subscale "depersonalization" improved over time, there was no detectable improvement in the scales "involvement" and "personal accomplishment." This result is in contrast to the marked improvement in the NCT, which objectively measures executive function and performance, and the clearly improved alertness value, as measured by the MDMQ. The contradiction between self-rating and objective outcome regarding "personal accomplishment" is in line with what is known about the essential role of individual perception of achievement in burnout, which often deviates from objective evaluation.[@b5-ndt-13-889]

The BOSS assessment results demonstrate that over the 12-week course of treatment the subjective perception of different aspects of life (profession, own person, family, and friends) as well as physical, cognitive, and emotional complaints improved clearly. The average global and subvalues of the BOSS I and the BOSS II assessments thus reflect a perception of reduced global- and aspect-related stress burdens.

Comparing the results of BOSS I and II with a representative normative German sample clearly shows that at the beginning of the study the participants reported clinically relevant psychological, physical, and psychosocial complaints (global score T-values 65 and 63 for BOSS I and II, respectively). This global score finally decreased to a normal value after the 12-week treatment phase with *R. rosea* (global T-value 54 and 53 for BOSS I and II, respectively).

Increased sexual interest and functioning as determined by the NAS for Impairment of Sexual Life and the PSFQ are obvious and indicate an alleviation of stress-induced impairment of sex life after the intervention. These results are in line with earlier findings on the causal relationship of life-stress, anxiety, and depression with sexual dysfunction[@b41-ndt-13-889],[@b42-ndt-13-889] and support the assumption of an impairing effect of burnout on sexual functioning.

The evaluation of therapeutic effects as assessed by the respective CGI item before and after the intervention period shows that at least a minimal improvement of the disorder is reported by the vast majority of patients (105/117 or 89.7%). This suggests therapeutic efficacy of *R. rosea* extract in burnout.

Despite the observed quick and distinct improvement of most of the outcome parameters during the first week of intervention, which might at first glance not seem to be in accordance with what is known about the usually rather slow process of burnout therapy, it is still in line with what is known about the gradual development of burnout.[@b6-ndt-13-889] In this context, the outcomes of the PSQ and NAS assessment suggest that the reduction of core values such as exhaustion, fatigue, and subjective stress perception during the treatment with *R. rosea* extract might be an important first step toward a continuous alleviation of burnout symptoms, thus inhibiting the exacerbation of the syndrome and preventing the development of subsequent disorders such as depression or physical illness.

The lack of a control in the trial reported here must be considered a limitation. The results thus remain preliminary and may not be considered confirmatory. Nevertheless, the considerable improvements found for most of the outcome measures reveal positive trends in burnout therapy. No symptom alleviation can be expected without treatment. The trial results are therefore important to help generate hypotheses for further research and provide bases for confirmatory study design, endpoints, and methodologies.[@b43-ndt-13-889]

The steady and substantial alleviation of the majority of the burnout symptoms assessed was statistically relevant for the variables evaluated for the FAS as early as 1 week after the start of treatment. The consistent overall results were further confirmed by the analyses of the PPS, subgroup analyses, and repeated measurement analyses. The results obtained are in line with the findings from previously conducted clinical trials on the clinical outcomes of *R. rosea* in different aspects of the burnout syndrome such as stress and depression.

The number and nature of AEs that occurred during the trial indicate a favorable safety profile of *R. rosea* in patients suffering from burnout symptoms, which is also underlined by the remarkably high treatment compliance.

Conclusion
==========

The trial reported here was the first to investigate clinical outcomes in patients suffering from burnout symptoms when treated with *R. rosea*. During administration of the study drug over the course of 12 weeks, a wide range of outcome measures associated with the syndrome clearly improved. The consistent data obtained support the claim that the results of this open-label exploratory study are in line with previous findings on the alleviation of life-stress and burnout symptoms by application of *R. rosea*. The results presented therefore provide an encouraging basis for future RCTs further investigating the clinical outcomes of *R. rosea* extract in patients with the burnout syndrome.
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![Disposition of patients and analysis of data sets.](ndt-13-889Fig1){#f1-ndt-13-889}

![NAS for subjective stress symptoms.\
**Note:** N=117, mean ±95% confidence interval, FAS.\
**Abbreviations:** NAS, Numerical Analogue Scale; FAS, full analysis set.](ndt-13-889Fig2){#f2-ndt-13-889}

![Burnout Screening Scale BOSS II.\
**Note:** N=117, mean ±95% confidence interval, FAS.\
**Abbreviations:** FAS, full analysis set; BOSS, Burnout Screening Scales.](ndt-13-889Fig3){#f3-ndt-13-889}

###### 

Demographic data: absolute (relative) frequency and mean ± standard deviation, FAS (N=117)

  Measure                                                Number
  ------------------------------------------------------ ------------
  Female                                                 68 (58.1%)
  Male                                                   49 (41.9%)
  Age                                                    43.7±8.0
  Height (cm)                                            172.2±10.1
  Weight (kg)                                            78.4±18.7
  Duration of stress/stress-related complaints (years)   2.7±3.0
  Prior treatment for stress-related complaints          40 (34.2%)
  Family history related to study indication             22 (18.8%)

**Abbreviation:** FAS, full analysis set.

###### 

MBI-D: mean ± standard deviation, median and *P*-value of the two-sided Wilcoxon signed-rank test, FAS, LOCF (N=117)

  Subscale                  Screening   Week 12   Change week 12 -- screening   *P*-value
  ------------------------- ----------- --------- ----------------------------- -----------
  Depersonalization         1.8±1.2     1.4±1.3   −0.4±1.2                      \<0.001
  1.6                       1.2         −0.2                                    
  Emotional exhaustion      2.6±0.3     2.3±1.0   −0.3±1.0                      \<0.001
  2.7                       2.2         −0.2                                    
  Involvement               2.1±1.3     2.0±1.3   −0.1±1.3                      0.171
  2.0                       2.0         0.0                                     
  Personal accomplishment   4.3±0.4     4.3±0.9   0.0±0.8                       0.464
  4.3                       4.4         0.0                                     

**Note:** High scores indicate a high burnout level, except for the subscale "personal accomplishment" in which a lower score indicates a higher level.

**Abbreviations:** MBI-D, Maslach Burnout Inventory; FAS, full analysis set; LOCF, last observation carried forward.

###### 

PSQ: mean ± standard deviation, median, *P*-value of the two-sided Wilcoxon signed-rank test, FAS, LOCF (N=117)

  Subscale           Screening   Week 12    Change week 12 -- screening   *P*-value
  ------------------ ----------- ---------- ----------------------------- -----------
  PSQ stress score   0.6±0.2     0.4±0.2    −0.2±0.2                      \<0.001
  0.6                0.4         −0.1                                     
  Fatigue            12.5±2.14   10.1±3.1   −2.4±3.0                      \<0.001
  13.0               10.0        −2.0                                     
  Harassment         10.1±2.3    8.6±2.6    −1.5±2.5                      \<0.001
  10.0               8.0         −1.0                                     
  Irritability       5.7±1.3     4.6±1.6    −1.1±1.5                      \<0.001
  6.0                5.0         −1.0                                     
  Lack of joy        19.3±3.7    16.5±4.6   −2.8±4.1                      \<0.001
  20.0               17.0        −2.0                                     
  Overload           11.6±2.6    10.2±2.9   −1.4±2.3                      \<0.001
  12.0               10.0        −1.0                                     
  Tension            11.7±2.1    9.3±3.0    −2.4±2.6                      \<0.001
  12.0               9.0         −2.0                                     
  Worries            12.9±3.1    10.7±3.3   −2.1±3.2                      \<0.001
  13.0               10.0        −1.0                                     

**Abbreviations:** PSQ, Perceived Stress Questionnaire; FAS, full analysis set; LOCF, last observation carried forward.

###### 

BOSS I and II: total average value, mean ± standard deviation, median, *P*-value of the two-sided Wilcoxon signed-rank test, FAS, LOCF (N=117)

  Scale                  Subscale              Screening   Day 7     Week 8    Week 12    Change week 12 -- screening   *P*-value
  ---------------------- --------------------- ----------- --------- --------- ---------- ----------------------------- -----------
  BOSS I                 Profession            2.0±0.9               1.4±0.9   1.3±0.9    −0.7±1.0                      \<0.001
  2.0                                          1.3         1.2       −0.5                                               
  Own person             2.5±0.9                           1.6±0.9   1.5±1.0   −1.0±1.0   \<0.001                       
  2.5                                          1.5         1.4       −0.9                                               
  Family                 2.7±1.1                           1.9±1.1   1.7±1.1   −0.9±1.1   \<0.001                       
  2.6                                          1.8         1.4       −0.6                                               
  Friends                2.3±1.0                           1.5±1.0   1.4±1.0   −0.8±1.0   \<0.001                       
  2.2                                          1.4         1.2       −0.6                                               
  Global score           2.3±0.8                           1.6±0.8   1.4±0.9   −0.9±0.9   \<0.001                       
  2.3                                          1.4         1.3       −0.8                                               
  BOSS II                Physical complaints   1.7±0.8     1.2±0.8   1.1±0.7   1.0±0.7    −0.7±0.8                      \<0.001
  1.6                    1.0                   0.9         0.9       −0.6                                               
  Cognitive complaints   2.3±1.0               1.7±0.9     1.5±1.0   1.4±1.0   −1.0±1.0   \<0.001                       
  2.2                    1.6                   1.3         1.2       −0.9                                               
  Emotional complaints   2.2±1.1               1.5±0.9     1.3±0.9   1.2±1.0   −1.0±1.0   \<0.001                       
  2.1                    1.4                   1.1         0.9       −0.8                                               
  Global score           2.1±0.9               1.5±0.8     1.3±0.8   1.2±0.8   −0.9±0.8   \<0.001                       
  2.1                    1.4                   1.2         1.0       −0.9                                               

**Abbreviations:** BOSS, Burnout Screening Scales; FAS, full analysis set; LOCF, last observation carried forward.

###### 

Numerical Analogue Scale for "Impairment of Sexual Life" and PSFQ: number of subjects, mean ± standard deviation, median, and *P*-value of the two-sided Wilcoxon signed-rank test, FAS, LOCF

  Scale                                                    Item                        Screening   Week 12   Change week 12 -- screening   *P*-value
  -------------------------------------------------------- --------------------------- ----------- --------- ----------------------------- -----------
  NAS                                                      Impairment of sexual life   117         117       117                           \<0.001
  6.8±1.5                                                  4.2±3.1                     −2.6±2.8                                            
  6.3                                                      5.0                         −2.0                                                
  Thinking about sex with interest/desire                  116                         116         116       \<0.001                       
  2.7±1.5                                                  3.3±1.4                     0.6±1.3                                             
  3.0                                                      4.0                         0.0                                                 
  Enjoyment of sex                                         115                         112         112       \<0.001                       
  2.6±1.3                                                  3.3±1.3                     0.6±1.3                                             
  3.0                                                      4.0                         0.0                                                 
  Ability to become sexually aroused                       116                         114         114       \<0.001                       
  2.9±1.4                                                  3.4±1.2                     0.5±1.3                                             
  3.0                                                      4.0                         0.0                                                 
  Frequency of sexual activity                             115                         113         113       \<0.001                       
  2.2±1.2                                                  2.8±1.4                     0.6±1.3                                             
  2.0                                                      3.0                         0.0                                                 
  PSFQ                                                     Ability to have orgasm      116         114       114                           0.005
  3.0±1.3                                                  3.3±1.2                     0.3±1.1                                             
  3.0                                                      4.0                         0.0                                                 
  Overall satisfaction with sexual life                    113                         114         112       \<0.001                       
  2.5±1.1                                                  3.2±1.2                     0.6±1.2                                             
  2.0                                                      3.0                         0.5                                                 
  Ability to have and/or maintain an erection              49                          49          49        0.002                         
  3.2±0.9                                                  3.6±0.9                     0.4±0.8                                             
  3.0                                                      4.0                         0.0                                                 
  Ability to ejaculate                                     49                          49          49        0.745                         
  3.7±0.9                                                  3.7±0.7                     0.0±0.7                                             
  4.0                                                      4.0                         0.0                                                 
  Relevance of sexual functioning for current well-being   117                         117         117       0.609                         
  3.9±1.4                                                  3.8±1.6                     −0.1±1.7                                            
  4.0                                                      4.0                         0.0                                                 

**Abbreviations:** PSFQ, Patient Sexual Function Questionnaire; FAS, full analysis set; LOCF, last observation carried forward; NAS, Numerical Analogue Scale.

###### 

NCT and MDMQ: mean ± standard deviation, median, *P*-value of the two-sided Wilcoxon signed-rank test, FAS, LOCF (N=117)

  Measure/scale               Screening   Day 7       Week 8      Week 12     Change week 12 -- screening   *P*-value
  --------------------------- ----------- ----------- ----------- ----------- ----------------------------- -----------
  NCT (time in s)             72.6±19.6   64.5±17.1   63.2±16.7   60.5±15.8   −12.1±9.2                     \<0.001
  68.8                        60.0        59.0        57.3        −10.8                                     
  MDMQ                                                                                                      
   Alertness -- tiredness     20.8±7.2    23.5±7.2    26.4±7.8    26.4±8.0    5.6±8.8                       \<0.001
  20.0                        24.0        27.0        26.0        5.0                                       
   Calmness -- restlessness   22.3±6.6    24.5±6.3    27.3±6.8    28.2±7.4    6.0±6.8                       \<0.001
  21.0                        24.0        28.0        29.0        6.0                                       
   Good mood -- bad mood      24.1±6.2    27.0±6.7    29.6±7.0    29.6±6.8    5.6±7.1                       \<0.001
  23.0                        27.0        31.0        29.0        5.0                                       

**Note:** Increased scores for the MDMQ indicate an improvement of mood and wellbeing.

**Abbreviations:** NCT, Number Connection Test; MDMQ, Multidimensional Mood State Questionnaire; FAS, full analysis set; LOCF, last observation carried out.

###### 

Adverse events during the active treatment and risk phase: absolute (relative) frequency of subjects, safety analysis set (SAF), N=118

  Adverse event (MedDRA system organ class)         Number of patients (%)
  ------------------------------------------------- ------------------------
  Any patients with adverse event(s)                70 (59.3)
  Nervous system disorders                          32 (27.1)
  Infections and infestations                       32 (27.1)
  Gastrointestinal disorders                        15 (12.7)
  Musculoskeletal and connective tissue disorders   9 (7.6)
  Skin and subcutaneous tissue disorders            5 (4.2)
  Eye disorders                                     4 (3.4)
  Injury, poisoning and procedural complications    4 (3.4)

**Note:** Events that were observed in \>3 subjects.

**Abbreviation:** MedDRA, Medical Dictionary for Regulatory Activities.
